RE:RE:RE:RE:RE:RE:Just thought I would pass this alongThere will be another financing, maybe two, if they don't raise cash via partnerships to complete the NASH phase III and do cancer too. Still, the average price of the two offerings you envision should have been much higher with more competence applied to the situation. I would have felt a little better if they had raised $20 million instead of $46 million with the intention of raising more at a later point when the share price was higher. But they evidently wanted to buy the most expensive insurance policy they could find.
qwerty22 wrote: Let's assume they need another financing if they're funding a NASH Ph3, and that will likely be bigger. If this financing and the next year helps the SP get to a good place and they do that 2nd financing then maybe we have to see the overall strategy as an average of the two financings. Just tryin' to shine the turd!
jfm1330 wrote: I am tired of reading about anger, frustration or indignation about the last financing. What's the point of repeating it over and over? Hey! We know it! If someone thinks the BOD and management are crooks and/or a bunch of incompetents, just sell the stock and move on.
If Thera is going to finally be a success story, this financing will only be one event in a serie of events, some totally in favor of the company, and other less so, like this financing. If oncology ends up as a blockbuster, imagine how good a deal for shareholders it will have been, same for NASH. The company got both for almost nothing. They got Trogarzo's rights for almost nothing upfront.
Also, the worst thing for somebody taking an insurance policy, is to say it was a bad move at the end of it because you did not need to use it.